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SUMMARY 
Degrons are minimal elements that mediate the interaction of proteins with degradation 
machineries to promote proteolysis. Despite their central role in proteostasis, the number of 
known degrons remains small and a facile technology to characterize them is lacking. Using a 
strategy combining Global Protein Stability (GPS) profiling with a synthetic human 
peptidome, we identify thousands of peptides containing degron activity. Using CRISPR 
screening, we established that the stability of many proteins is regulated through degrons 
located at their C-terminus. We characterize eight Cullin-RING E3 ubiquitin ligase (CRL) 
complexes adaptors that regulate C-terminal degrons including six CRL2 and two CRL4 
complexes and computationally implicate multiple non-CRLs in end recognition. Human 
proteome analysis revealed that the C-termini of eukaryotic proteins are depleted for C-
terminal degrons, suggesting an E3 ligase-dependent modulation of proteome composition. 
Thus, we propose that a series of ‘C-end rules’ operate to govern protein stability and shape 
the eukaryotic proteome.  
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INTRODUCTION 
Protein degradation plays a key role in nearly all cellular processes. The importance 
of this role is underscored by the fact that nearly 5% of mammalian genes are dedicated to the 
control of protein stability (Clague et al., 2015; Peng et al., 2003). Failure to maintain protein 
homeostasis can lead to a variety of pathological disorders, including inflammation, 
neurodegeneration and cancer (Popovic et al., 2014). 
The ubiquitin-proteasome system (UPS) represents the major route by which the cell 
degrades unwanted proteins (Kwon and Ciechanover, 2017), with E3 ubiquitin ligases (E3) 
playing a crucial role in providing specificity to this process (Zheng and Shabek, 2017). The 
Cullin-RING E3 ligases (CRL) represent the largest E3 sub-family. Six main Cullins are 
found in human cells. They function as scaffolds to recruit target substrates through Cullin 
adaptor proteins which bind at their N-terminus, together with E2s which bind at their C-
terminus (Lydeard et al., 2013). Previously, using the small molecule pan-Cullin inhibitor 
MLN4924 (Soucy et al., 2009) combined with the Global Protein Stability (GPS) approach 
developed in our lab and other proteomic approaches, we and others identified hundreds of 
CRL substrates (Bennett et al., 2010; Emanuele et al., 2011; Harper and Tan, 2012; Liao et al., 
2011; Yen and Elledge, 2008; Yen et al., 2008). 
  A major challenge towards the goal of a systems-level understanding of the UPS is to 
understand in molecular detail how the approximately 600 E3s select their substrates. In most 
cases it is thought that E3s bind their substrates through recognition of specific short peptide 
motifs termed degrons (Lucas and Ciulli, 2017; Varshavsky, 1991). An important property of 
degrons is transferability, such that fusion of a degron can confer instability on an otherwise 
long-lived protein. The first degrons discovered were N-degrons (Bachmair et al., 1986), 
leading to the discovery of the N-end rule pathway (Varshavsky, 2011).  
  
4 
Despite their importance, to date only a handful of degrons have been identified and 
matched to their cognate E3s (Meszaros et al., 2017). Degron discovery remains challenging, 
mainly because (1) for most E3s no substrates have been identified, and (2) the mean size of 
human proteins is large (~470 amino acids), which makes mapping degron motifs in the 
context of the full-length proteins labor-intensive.  
 Here, by combining GPS technology with a synthetic representation of the human 
peptidome, we present a high-throughput method to identify degron sequences in human 
proteins. Coupling this approach with CRISPR-mediated genetic screens, we uncovered a 
mechanism, DesCEND (Destruction via C-End Degrons), described here and in a related 
manuscript (Lin et al., submitted) in which many unstable peptides targeted by CRLs are 
recognized through distinct C-terminal degrons. In total we identify six CRL2 and two CRL4 
complexes that target C-terminal degrons, and computationally uncover multiple C-terminal 
degrons not recognized by CRLs. Eukaryotic proteomes are depleted of proteins bearing C-
terminal degron motifs, suggesting that the recognition of C-terminal degrons by E3s has 
sculpted eukaryotic proteomes through evolution.  
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RESULTS 
Characterizing degron motifs in human proteins using GPS-peptidome technology. 
Towards the goal of establishing a systems level understanding of the specificity of 
E3s, we sought to develop a genome-wide approach to characterize degron motifs in 
mammalian proteins. To accomplish this we combined GPS technology (Emanuele et al., 
2011; Yen and Elledge, 2008; Yen et al., 2008) with a peptidome library covering the entire 
human proteome synthesized on high-density oligonucleotide microarrays. GPS is based on a 
lentiviral construct encoding two fluorescent proteins: DsRed, which serves as an internal 
reference, and a GFP fusion protein that is translated from an internal ribosome entry site 
(IRES) (Figure 1A). As both DsRed and GFP are expressed from the same transcript, the 
GFP/DsRed ratio can be used to readout the effect of the fusion partner on the stability of 
GFP. 
An oligonucleotide library encoding a synthetic representation of the human proteome, 
arranged as a series of 90 residue peptides overlapping by 45 residues, was cloned 
downstream of the GFP reporter. The resulting ‘GPS-peptidome’ library was packaged into 
lentiviral particles and used to infect HEK-293T cells at a low multiplicity of infection 
(MOI); untransduced cells were eliminated through puromycin selection. Fluorescence-
activated cell sorting (FACS) was used to partition the population into four bins of equal size 
based on the stability of the GFP-peptide fusion (Figures 1A and S1A). Subsequently we 
focused on the most unstable pool (Bin1), which contained thousands of GFP-peptide fusions 
that are proteasome substrates (Figure 1B) and were at least an order of magnitude less stable 
than GFP alone (Figure S1B).  
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CRISPR/Cas9 screens identify CRL2 adaptors mediating the degradation of unstable 
peptides. 
To simplify the task of identifying the proteins responsible for the degradation of the 
unstable peptides, we focused a single E3 class, the CRL family. Treatment of the GPS-
peptidome Bin1 cells with MLN4924 resulted in the stabilization of ~8% of GFP-peptide 
fusions (Figures 1C and S1C). Cells expressing MLN4924-responsive substrates were 
isolated by FACS (Figure 1D). Next we asked which of six Cullins were responsible for 
degrading the GFP-peptide fusions. Exogenous expression of C-terminally truncated 
dominant-negative (DN) versions of Cul2 and Cul5 resulted in marked stabilization of the 
MLN4924-responsive pool, whereas the other DN Cullins had more modest effects (Figures 
1E and S1D).      
 To identify the CRL2/5 adaptors responsible for targeting the unstable GFP-peptide 
fusions we performed a series of CRISPR genetic screens. Single cell clones of 17 GFP-
peptide fusions stabilized by expression of DN Cul2 and Cul5 were selected at random, and 
each clone was transduced with an sgRNA library targeting known adaptors for CRL2/5 
(Figure S2A; Table S1). Cells in which disruption of a CRL adaptor resulted in stabilization 
were isolated by FACS, and the sgRNAs enriched in this population were identified by DNA 
sequencing (Figure S2A; Table S1). In each case, CRL2, but not CRL5, was required for 
degradation of the GFP-peptide fusion (Figures 1F and S2B). The 17 clones could be 
clustered into four broad groups based on their requirements for CRL2 adaptors: 7 (clones 2-
8) are regulated by KLHDC3, 7 (clones 9-15) by both FEM1A and FEM1C, while FEM1B 
had a significant effect in 3 (clones 9, 16 and 17). Finally, APPBP2 loss strongly impaired the 
degradation of the GFP-peptide fusion in clone 1, and weakly in clones 2-4, which are also 
targeted by KLHDC3 (Figure 1F). These results were validated by individual adaptor 
disruption experiments in one clone from each group (Figure 1G).  
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The CRL2 adaptor KLHDC3 targets glycine-ended peptides for proteasomal 
degradation. 
 Sequence analysis of the 17 clones (Table S2) revealed that 6 of 7 peptides regulated 
by KLHDC3 terminated with a C-terminal glycine (the 7th ended with alanine) (Figure 1H). 
The previously reported KLHDC3 substrate, SEPHS2 (Lin et al., 2015), also terminated with 
a glycine, raising the possibility that KLHDC3 recognizes its substrates through a specific 
interaction with an exposed C-terminal glycine residue. Co-immunoprecipitation experiments 
demonstrated that KLHDC3 physically interacted with its GFP-peptide substrates (Figures 
S1E-G), while mutational analysis showed that alteration of the C-terminal glycine residue 
alone stabilized the GFP-peptide fusion: substitution of the glycine to aspartic acid resulted in 
marked stabilization, while substitution to alanine, which differs from glycine only by a 
single methyl group, resulted in partial stabilization (Figures 1I and S1H). Adding additional 
amino acids to the C-terminus of the peptide also led to stabilization (Figures 1J and S1I), 
indicating that the glycine residue only serves as a functional degron when located at the C-
terminus. Therefore, Cul2KLHDC3 targets glycine-ended peptides for proteasomal degradation. 
 
A GPS-ORFeome screen demonstrates CRL2-mediated degradation of glycine-ended 
full-length proteins.  
We extended these observations by examining whether full-length proteins ending 
with glycine were also targeted for degradation by CRL2. To do this, we performed a GPS 
experiment in which full-length proteins were fused to GFP (Figure 2). We cloned a library 
of ~15,000 cDNA constructs encoding full-length human proteins into the GPS vector. To 
allow the identity of the encoded protein to be determined through Illumina sequencing, a 
library of ‘barcode’ sequences were added at the 3’ end of each construct, with each ORF 
represented by on average 5 different barcodes to provide internal replicates (Figure 2A).  
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 HEK-293T cells were infected with the barcoded GPS-ORFeome library and sorted 
into five bins based on the GFP/DsRed ratio (Figure 2B). Illumina sequencing revealed that 
the barcoding strategy allowed reproducible identification of the encoded ORF (Figures 2C 
and S3A; Table S3). Proteasomal degradation was again the dominant mechanism driving 
instability of the fusion proteins (Figure S3B).  
 To identify CRL substrates we treated the three most unstable populations with 
MLN4924 and isolated cells expressing stabilized GFP-ORF fusion proteins by FACS, 
followed by a 2nd round of sorting without MLN4924 (Figures S3C and S3D). Then the 
CRL substrates identified through sequencing of the ORF barcodes. Notably, sequence 
analysis of the C-termini of the CRL substrates revealed that glycine at the terminal position 
was the most enriched feature (Figure 2D). The 27 glycine-ended CRL substrates identified 
are listed in Figure 2E. Again CRL2 was responsible for the degradation of the majority of 
the CRL substrates (Figure S3E), and by immunoblot we validated that Cul2 ablation 
resulted in the stabilization of a panel of exogenously expressed glycine-ended HA-epitope 
tagged substrates (Figure 2F). For two example substrates, we also confirmed that the C-
terminal glycine was indeed critical for CRL2-mediated degradation (Figure 2G). Thus, 
CRL2 complexes are also responsible for the degradation of full-length proteins ending with 
glycine. 
 
Glycine-ended proteins are underrepresented in eukaryotic proteomes. 
 Strikingly, we found that the presence of glycine specifically at the C-terminus was 
negatively correlated with protein stability in our GPS-ORF dataset (Figure 3A). This 
information, together with the knowledge that full-length proteins ending in glycine are 
substrates for CRL-mediated degradation, prompted us to examine the overall amino acid 
composition of the terminal regions of the eukaryotic proteome. This analysis revealed 
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several surprising features. First, the composition of the C-terminal residue of eukaryotic 
proteins is more variable than all other positions, suggesting that the amino acid present at the 
C-terminus is particularly important (Figure 3B). Second, glycine is strongly depleted at the 
terminal position, with glycine-ended proteins occurring at ~65% of the expected frequency 
(P < 10-164) (Figure 3B). Both of these effects are observed across a range of eukaryotic 
organisms (Figures 3C and 3D).  
We hypothesized that the depletion of glycine at the C-termini of eukaryotic proteins 
is a result of avoidance of E3s targeting G-end degrons. If so, amino acids at the penultimate 
(-2) position that favor degron function should be depleted among existing glycine-ended 
proteins relative to amino acids that disrupt degron function. 
 
Defining the composition of glycine-end degrons targeted by CRLs.  
 To distinguish these possibilities, we needed to precisely define the amino acid 
requirements of glycine-end degrons. We began by assessing the extent of the degron 
recognized by KLHDC3 by performing alanine-scanning mutagenesis across the last 10 
residues for 5 peptides substrates from the original CRISPR screens (Table S4). In each case, 
mutation of the terminal glycine to alanine resulted in stabilization; mutation of the amino 
acid at the penultimate position also prevented degradation in some cases (Figure S4A). For 
one peptide substrate we also performed a saturation mutagenesis experiment, mutating each 
residue to every other possible amino acid across the 12 terminal residues (Figure S4B; 
Table S5). This confirmed that the C-terminal glycine residue was absolutely critical for 
degradation, with only alanine being partially tolerated at the -1 position. Some preferences 
were also observed at the -2 and -3 positions, where acidic and small hydrophobic residues 
inhibited degradation (Figure S4B). 
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 To delineate a consensus sequence for the Cul2KLHDC3 degron, we sought to identify a 
larger number of KLHDC3 substrates. Starting with the MLN4924-responsive pool of 
unstable GPS-peptide substrates (Figure 1D), we disrupted KLHDC3 function using two 
independent sgRNAs and isolated cells displaying stabilization of the GFP-peptide fusions by 
FACS (Figure S4C; Table S6). In total this revealed 65 unique KLHDC3 substrates, 69% of 
which ended with glycine and 19% ended with alanine. At the -2 position the basic residues 
arginine and lysine were enriched in addition to glutamine and serine, while acidic and 
hydrophobic residues were disfavored (Figures S4D and S4E). 
 
The CRL2 adaptors KLHDC2, KLHDC3 and KLHDC10 cooperate to degrade glycine-
ended proteins.  
To explore the possibility that additional E3s beyond Cul2KLHDC3 might also target 
glycine-ended proteins, we performed an additional GPS experiment in which 2,245 56-mer 
peptides representing the C-terminal tails of all known isoforms of human proteins ending 
with glycine were fused to GFP (Table S7). This ‘G-end’ library was expressed in HEK-
293T cells and the cells partitioned into 3 bins based on stability by FACS (Figure 4A). 
Sequencing of the fusion peptides in each bin revealed major differences in amino acid 
composition at the -2 position in the unstable (Bin1) versus the stable (Bin3) populations. 
Glycine and arginine were enriched in the unstable pool and depleted from the stable pool, 
suggesting efficient degradation of GFP-peptide fusions ending in -GG and –RG, while for 
other amino acids, such as aspartic acid and glutamic acid, the opposite pattern was observed, 
suggesting inefficient recognition of peptides terminating in –DG and –EG (Figure S4F).  
Our previous data (Figure S4C-E) suggested that KLHDC3 would efficiently degrade 
substrates ending –RG. Based on the fact that –GG ends were enriched in the unstable pool in 
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addition to –RG ends, we considered whether additional CRL adaptors might also target this 
subset of glycine-ended proteins. Obvious candidates were the related CRL2 adaptors 
KLHDC2 and KLHDC10, which share 26% and 24% amino acid identity with KLHDC3, 
respectively. KLHDC2 has also previously been shown to mediate the degradation of the 
selenoproteins SELK and SELS, both end in –GG (Lin et al., 2015). To test this hypothesis, 
we took the MLN4924-responsive unstable population derived from the G-end peptidome 
library (Figure S4G), inactivated either KLHDC2, KLHDC3, or KLHDC10 using CRISPR 
and isolated the cells expressing stabilized glycine-ended GFP-peptide fusions by FACS 
(Figure S4H). This experiment confirmed the expected preferences at the -2 position for 
KLHDC3, with substrates enriched for C-terminal -RG, -KG and -QG motifs, whereas the 
KLHDC2 substrates were most enriched for -GG ends, and the KLHDC10 substrates were 
enriched for –WG, -PG and –AG ends (Figures 4B-C). Saturation mutagenesis experiments 
were performed on two –GG and –RG substrates, in which each residue was mutated to every 
other possible amino acid across the 10 terminal residues (Figure 4D; Table S5). This 
confirmed that the C-terminal –GG motif was absolutely critical for the degradation of 
KLHDC2 substrates. The terminal glycine residue was also critical for the degradation of 
KLHDC3 substrates bearing an –RG end, but additional preferences were observed at the -2 
position, where acidic and small hydrophobic residues inhibited degradation (Figure 4D; 
Table S5). Therefore, the CRL2 adaptors KLHDC2, KLHDC3 and KLHDC10 are jointly 
responsible for targeting proteins terminating in glycine for degradation (Figure 4E). 
 
Glycine-end degrons are depleted from the C-termini of eukaryotic proteins.    
Overall, these experiments defined C-termini ending in –GG, –RG, -KG, –QG, -WG, 
-PG and -AG as the optimal degrons for CRL2-mediated degradation via the adaptors 
KLHDC2, KLHDC3 and KLHDC10. Furthermore, certain -2 amino acids (D, E, V, I and L) 
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are more enriched in the stable G-end peptide populations (Figure S4F) and disfavored by 
KLHDC3 (Figures 4D and S4B). With knowledge of these preferred and disfavored degron 
sequences in hand, we re-evaluated the amino acid proportions at the C-termini of human 
proteins. In support of the hypothesis that the depletion of glycine-ended proteins is due in 
part to the evasion of CRL-mediated proteasomal degradation, we found that the amino acids 
at the -2 position that favor degron activity are depleted among glycine-ended proteins, while 
those amino acids that antagonize degron activity are correspondingly enriched (Figure 4F).  
Two additional lines of evidence further support the hypothesis that avoidance of 
glycine-end degrons shapes C-terminal residue frequencies. Whilst glycine is depleted at the 
C-terminal position across eukaryotes, no depletion of glycine-ends is observed in bacteria or 
archaea (Figure 4G). This finding is consistent with the idea that proteasomal degradation 
drives glycine-end depletion, as organisms from these kingdoms do not share similar 
ubiquitin-proteasome systems (Jastrab and Darwin, 2015). Interestingly, viruses also show 
depletion of glycine ends (Figure 4G) suggesting they have evolved to evade glycine-end 
degradation mechanisms in their eukaryotic hosts; conversely bacteriophage show no glycine 
depletion at the C-terminus (Figure 4G). Finally, we also searched eukaryotic proteomes to 
identify atypical species in which depletion of glycine-ended proteins is not observed. 
Among the few taxa in which terminal glycine is not depleted are members of the 
Plasmodium genus. These organisms have only two Cullin proteins, one fewer than those 
found in fungi (Marin, 2009; Ponts et al., 2008), and lack obvious orthologs of Elongin B and 
C suggesting they lack a functional CRL2. Thus, the distortion of the frequency of glycine at 
the termini of eukaryotic proteins is in part, if not primarily, driven by selective pressure to 
avoid CRLs that target glycine-end degrons. 
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Identification of additional classes of C-terminal degrons in human proteins.   
The termini of proteins exhibit greater disorder than do internal sequences (Lobanov 
et al., 2010), and, relieved of the evolutionary constraints to maintain a structure, we posit 
they may exhibit more flexibility to evolve regulatory capacity, as has been demonstrated for 
the tails of histone proteins (Campos and Reinberg, 2009). With this in mind, we examined 
whether C-terminal regions of proteins might be a fertile region to explore for degrons. 
To identify putative C-terminal degrons, we performed a GPS experiment in which a 
library encoding the final 23 residues of all human proteins were fused to GFP (Figures 5A 
and S6A; Table S9). As before, the lentiviral library was introduced into HEK-293T cells 
and divided into bins based on the stability of the GFP-peptide fusions. The sequence 
composition of the peptides that destabilize GFP (Bin1) was markedly different from those 
that stabilize GFP (Bin4): regardless of their position across the peptide, the presence of the 
bulky hydrophobic residues phenylalanine, tryptophan and tyrosine promoted instability, 
whereas greater numbers of the charged residues aspartic acid, glutamic acid and lysine 
correlated with stability (Figures 5B and 5C), indicating a general property that influences 
protein stability in this context. 
 We were particularly interested in motifs that might promote instability specifically 
when located at or near the C-terminus of the peptide. For all possible combinations of di-
peptide motifs, computationally we compared the mean stability of all GFP-peptide fusions 
harboring the motif within the last six C-terminal amino acids versus those harboring the 
motif at an internal position in the 23-mer peptide (Figure 5D; Table S10). As expected, 
motifs encompassing a C-terminal glycine residue dominated the list of the most destabilizing 
motifs (Figure 5E), but many additional motifs were also apparent, including an RxxG motif, 
a C-terminal twin glutamic acid (-EE) motif, and a set of motifs that shared in common an 
arginine at the -3 position (R-3 motif) (Figures 5E and 5F). 
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Cul2APPBP2 targets proteins bearing C-terminal RxxG motifs for proteasomal 
degradation.  
The RxxG motif was intriguing, as the sole substrate from the original GPS-
peptidome screen (clone 1) that we found to be specifically targeted for degradation by 
Cul2APPBP2 contained a perfect match (-RNLGIR*) (Figures 1F and 1G; Table S2). 
Furthermore, three additional clones in which ablation of APPBP2 had some stabilizing 
effect contained a perfect sequence match (clone3: -SGRRWG* and clone4: -SSRQFG*), or 
two close matches with alanine instead of glycine (clone2: -RRSAA*) (Table S2). To further 
test whether APPBP2 recognized proteins bearing C-terminal RxxG motifs, we identified 
more Cul2APPBP2 substrates. We ablated APPBP2 function in the unstable MLN4924-
reponsive population from the original GPS-peptidome screen (Figure 1D) and isolated cells 
containing stabilized GFP-peptide fusions by FACS (Figure S5A; Table S11). Sequencing 
revealed 64 unique APPBP2 substrates; 41 (64%) of these contained an RxxG motif at or 
near the C-terminus, with RxxGx* and RxxGxx* motifs predominating (Figures 5G and 
5H). To confirm that this degron was only functional at the C-terminus, we randomly 
selected several unstable peptides and full-length protein substrates harboring RxxG motifs 
mutated the degron or moved the degron away from the end by adding additional amino acids 
at the C-terminus. All validated as APPBP2 substrates (Figure S5B) and for each , both 
mutation of or repositioning of the RxxG motif away from the C-terminus resulted in 
stabilization (Figure S5C). Saturation mutagenesis experiments. confirmed the absolute 
requirement for the C-terminal arginine and glycine in the RxxG degron (Figure S5D; Table 
S5). Thus, APPBP2 represents a CRL2 adaptor that recognises C-terminal degrons (Figure 
5I).  
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Recognition of additional C-terminal degrons by CRL2 and CRL4 complexes. 
Next we tested whether the EE and the R-3 motifs identified computationally also 
represented C-terminal degrons. We isolated CRL substrates from the GPS-C-terminal 23-
mer library by treating the unstable Bin1 and Bin2 populations with MLN4924 and isolating 
the stabilized population (Figure S6B; Table S9). In addition to enrichment for C-terminal 
glycine, sequence analysis of the CRL substrates revealed overrepresentation of glutamic acid 
at both the -1 and -2 positions, and arginine at the -3 position (Figure 6A). Further 
examination revealed that the C-terminal acidic residues are indeed found together as a twin 
glutamic acid motif (Figure S6C), while an arginine at the -3 position is frequently paired 
with terminal histidine, proline, aspartic acid or glutamine residues (Figure S6D).     
To identify which Cullin was recognizing these motifs, we employed DN Cullin 
constructs. DN Cul2 expression again stabilized the greatest proportion of substrates, but, in 
contrast to the entire GPS-peptidome library (Figure S1D), expression of both DN Cul4A 
and DN Cul4B had an effect approaching a similar magnitude (Figure S6E). Sequencing 
revealed that, in addition to the glycine-end motif, an arginine-end motif was enriched among 
the CRL2 substrates (Figure 6B; Table S12), while both the -EE and the R-3 motifs were 
enriched specifically among the substrates stabilized by expression of both DN Cul4A and 
Cul4B (Figure 6C; Table S12).  
For each motif class we selected several C-terminal 23-mer peptides at random for 
validation. Addition of the C-terminal tails of CDK5R1 and SIL1, which both end in arginine, 
to GFP resulted in destabilization of the fusion protein; this effect was abrogated upon 
deletion of the terminal arginine residue or the addition of extra residues at the C-terminus 
(Figures 6D and S7A). Next we confirmed that the fusion of peptides terminating with twin 
glutamic acid residues (MAGEA3 and MYH3) or harboring R at -3 motifs (NPPB and 
MSRB2) to the C-terminus of GFP resulted in CRL4-mediated degradation (Figures 6E and 
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S7B). Addition of extra residues to the C-terminus again stabilized the GFP-peptide fusions, 
but, interestingly, while alanine mutagenesis of the terminal motifs (–EE to –AA and –RxH 
to –AxA) abolished CRL-mediated degradation, the mutant peptides remained unstable and 
presumably now served as substrates for other E3s (Figures 6E and S7B). For one substrate 
ending –EE and one substrate containing an R-3 motif we also performed a saturation 
mutagenesis experiment, which confirmed the importance of the terminal twin glutamic acid 
motif and the arginine at the -3 position for the degron activity (Figure S7C; Table S5). 
 To identify the CRL adaptors recognizing these degrons, we performed CRISPR 
screens. We transduced HEK-293T cells expressing GFP-peptide fusions bearing either R-
end, EE-end or R at -3 degron motifs with a CRISPR library targeting either CRL2 BC box 
adaptors (R-end peptide fusions) or CRL4 DCAF adaptors (EE-end and R at -3 peptide 
fusions). Cells in which the GFP-peptide fusion were stabilized were isolated by FACS, and 
enriched sgRNAs detected by sequencing (Figure S7D). The adaptors found in common 
between the different peptides bearing the same C-terminal degron motifs are depicted in 
Figure 6F. As expected, DDB1, an integral component of both Cul4A and Cul4B, scored 
across all samples. The screens unambiguously identified DCAF12 as the adaptor 
recognizing the EE-end degron and TRP4CAP as the adaptor recognizing the R-3 degron, 
(Figures 6F and S7E; Table S13). Thus, Cul4DCAF12 and Cul4TRP4CAP mediate the 
degradation of –EE end and R-3 substrates respectively (Figure 6G). 
The BC box CRISPR screens identified the FEM family adaptors as critical for the 
degradation of the peptides ending in arginine, with Cul2FEM1B responsible for the 
degradation of the GFP-CDK5R1 peptide fusion and both Cul2FEM1A and Cul2FEM1C required 
for the degradation of the GFP-SIL1 peptide fusion (Figures 6F and S7E; Table S13). As 
expected, Cul2 and Elongin C scored in both clones. The identification of the FEM family 
adaptors was intriguing, as previously we found that several of the unstable GFP-peptides 
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from the original GPS-peptidome library (Clones 9-17) were stabilized by knockout of either 
FEM1A/FEM1C or FEM1B (Figures 1F and S2). With the exception of clone 17, all of 
these constructs terminated with –QGRAR*, a common sequence derived from the backbone 
of the GPS expression vector. These findings supports the hypothesis that Cul2FEM1A-C 
complexes target substrates ending in arginine (Figure 6G). However, given that all (with the 
exception of peptides derived from the C-terminus of proteins) of the full-length GFP-peptide 
fusion proteins in the GPS-peptidome library terminate with –QGRAR*, and yet only a small 
proportion of these proteins are substrates for Cul2FEM1A-C, we anticipate that the full degron 
recognized by FEM adaptors must be considerably more complex. 
 
Proteasomal degradation of endogenous proteins through C-terminal degrons 
 To validate that endogenous cellular proteins can be degraded by CRLs targeting C-
terminal degrons, we examined the degradation of the following substrates for which 
antibodies were readily available: p14ARF and TSPYL1 (G-end), PTOV1 (RxxGG), CCT5 
(EE-end) and MAGEA3 (EE-end). First we confirmed that these proteins are CRL substrates 
(Figure 6H), and then performed individual CRISPR-mediated disruption experiments to 
delineate the adaptors involved (Figure 6I). The glycine-ended proteins p14ARF and 
TSPYL1 were stabilized following ablation of KLHDC3; PTOV1, which bears both a –GG 
degron and a RxxG degron, was stabilized upon the combined knockout of both KLHDC2 
and APPBP2, while MAGEA3 and CCT5 (ending -EE) were stabilized following the loss of 
DCAF12 (Figure 6I).  
 N-Myc has previously been identified as a substrate of Cul4TRPC4AP (Choi et al., 2010). 
N-Myc C-terminal peptide was identified as a CRL substrate when fused to GFP in our C-
terminal 23-mer GPS-peptidome screen (Figure 5 and Table S9), and, intriguingly, 
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examination of the N-Myc amino sequence revealed that it contained an arginine residue at 
the -3 position. Therefore, we directly tested the hypothesis that the Cul4TRPC4AP-mediated 
degradation of N-Myc occurs through its R-3 motif. We first showed that a GPS construct in 
which the C-terminal 23 residues of N-Myc was fused to GFP was stabilized upon CRISPR-
mediated ablation of TRPC4AP (Figure 6J). Furthermore, mutation of the arginine residue at 
the -3 position to lysine or deletion of the last three residues of the N-Myc peptide also 
resulted in stabilization of the GFP-fusion protein (Figure 6K). Altogether, these data 
demonstrate that N-Myc is targeted for degradation by Cul4TRPC4AP through an R-3 C-
terminal degron motif.  
 
Recognition of C-terminal degrons is not restricted to CRLs 
Spurred by the finding that alanine mutagenesis of the EE-end and R-3 motifs could 
change the specificity of a degron from a CRL substrate to a non-CRL substrate (Figure 6E), 
we re-examined the data from the C-terminal GPS screen to search specifically for additional 
putative C-terminal degrons not targeted by CRLs. Based on the fold enrichment of each 
motif among the substrates stabilized following MLN4924 treatment (Figure S6B), 
computationally we divided the top 100 predicted destabilizing C-terminal motifs (Figure 
5E) into CRL and non-CRL substrates (Figure 7A; Table S10). Although the majority (58%) 
were targeted by CRLs, comprising predominantly G-end, EE-end, R at -3 and RxxG motifs, 
the 42 non-CRLs motifs could also be grouped into a number of functional classes (Figures 
7A and 7B). These included alanine at both the terminal and penultimate positions, 
supporting the existence of alanine-end degrons suggested by our previous alanine 
mutagenesis experiment (Figures 6E). 
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To experimentally validate these additional classes of C-terminal degrons, we 
analyzed randomly selected 23-mer C-terminal peptides harboring either A-end, A at -2 or V 
at -2 motifs (Figure 7C). In each case the peptide conferred instability on GFP, which was 
rescued with MG132 but not MLN4924, while mutation or repositioning of the degron motifs 
resulted in stabilization (Figure 7C). Thus, recognition of C-terminal degrons is not restricted 
to CRLs (Figure 7D).  
 
C-terminal degron recognition has shaped the human proteome.  
Strikingly, all C-terminal motifs identified in this study, with the exception of the A at 
-2 degron motif, are significantly under-represented among human proteins (Figure 7E). 
Furthermore, when considering the most depleted amino acids across the C-termini of human 
proteins, all but one of the most significantly depleted residues comprise a C-terminal degron 
motif (Figure 7F). The exception is threonine. Since we did not observe destabilization of 
threonine-ended proteins, threonine-ends may be under-represented for degradation-
independent. Overall, we propose that an array of E3s recognize C-terminal degrons to 
regulate the stability of eukaryotic proteins (Figure S7F), which has in turn sculpted the 
composition of eukaryotic proteomes.  
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DISCUSSION 
 Achieving a systems-level understanding of protein stability control will require the 
identification of degron motifs recognized by E3s on a global scale. The GPS-peptidome 
method represents an advance towards this goal. Coupling this approach with CRISPR 
screens, here we have characterized a suite of CRLs that target their substrates through the 
recognition of specific degron motifs located at their extreme C-terminus. Computationally 
we also implicated non-CRL family E3s in C-end recognition, suggesting that DesCEND is a 
general principle used by the UPS to regulate protein turnover. 
Exploiting the GPS-peptidome approach to identify degrons in human proteins  
E3s sculpt the proteome in much the same way miRNAs filter the transcriptome 
(Fabian and Sonenberg, 2012; Ordureau et al., 2015), providing control critical to the identity 
and function of cells. The identification of degrons and their cognate E3s is a key issue for 
achieving a systems-level understanding of protein stability control. By adapting the GPS 
approach to measure the stability of short peptides, we have identified on the order of 
100,000 peptides that confer instability on GFP. Although many peptides may represent 
similar degrons such as due to exposed hydrophobic residues, it is likely that others will 
comprise a large number of distinct degrons recognized by different E3s.  
Recognition of C-terminal degrons by CRL adaptors 
 The GPS-peptidome approach led us to the observation that multiple CRL2 and CRL4 
complexes recognize a variety of degron motifs located at the C-terminus of proteins. The 
localization of degrons at proteins ends appears attractive from an evolutionary perspective: 
the ends of proteins exhibit a greater degree of disorder than internal sequences (Lobanov et 
al., 2010), and, without the evolutionary constraints associated with maintaining a 3-D 
structure, protein termini may have an enhanced ability to incorporate regulatory sequences.  
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 We found 3 related CRL2 adaptors, KLHDC2, KLHDC3 and KLHDC10, which 
recognize distinct motifs at the C-terminus that all terminate with a glycine residue. KLHDC2 
and KLHDC3 had been previously shown to be responsible for degradation of truncated 
selenoproteins (Lin et al., 2015), although it appears that their physiological role also extends 
to the regulation of dozens of full-length glycine-ended proteins as we found in our GPS-
ORFeome. We also found that another family of CRL2 adaptors, FEM1A, FEM1B and 
FEM1C, share substrates that are enriched for C-terminal arginine residues, although the full 
degron motif recognized by the FEM proteins must also comprise additional internal 
sequences. Both FEM1A and FEM1C were found to be required for the degradation of the 
same substrates; suggesting that they may function as a heterodimer or that they each 
individually target a similar set of substrates. Another CRL2 adaptor, APPBP2, recognizes 
RxxG motifs in which the glycine residue is optimally located at the -2 or -3 position relative 
to the end.  
 The recognition of C-terminal degrons is not limited to CRL2. We found that 
Cul4DCAF12 targets proteins ending in a twin-glutamic acid degron and Cul4TRPC4AP degrades 
proteins containing arginine at the -3 position. Intriguingly, all of these CRL adaptors that 
recognize C-terminal degrons contain repeats of protein domains that form solenoid 
structures (Hrabe and Godzik, 2014): Kelch domains in KLHDC2, KLHDC3 and KLHDC10, 
Ankyrin repeats  in FEM1A, FEM1B and FEM1C, Tetratricopeptide repeat (TPR) domains in 
APPBP2, WD40 repeats in DCAF12, and Armadillo-like repeats in TRPC4AP. Structural 
insight would be invaluable to ascertain why such solenoid structures are particularly suited 
to the task of distinguishing short peptide motifs located at the exposed C-termini of proteins. 
 Further bioinformatic analysis identified additional C-terminal degron sequences that 
are targeted by non-CRLs. Thus far we have implicated approximately 11 E3s in the 
recognition of C-terminal degrons, and currently this number already exceeds the number of 
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E3s thought to be involved in the recognition of N-degrons. It is important to note that, 
because we have limited our analysis to just two defining amino acids, our bioinformatic 
predictions are very likely to be underestimating the total number of C-terminal degrons, as 
there are likely to be many degrons that employ more than two amino acids for specificity.   
 Beyond the recognition of specific degrons sequences, we have uncovered a general 
rule governing peptide stability based on overall amino acid composition. Larger numbers of 
the bulky aromatic residues tryptophan (W), phenylalanine (F) and tyrosine (Y), as well as 
cysteine (C), confer instability in opposition to the acidic residues aspartic acid (D) and 
glutamic acid (E), which, together with the positively charged lysine (K), promote stability. 
We predict that there will be an E3 or a family of E3s that recognize such hydrophobic 
stretches and which may be responsible for the elimination of unfolded proteins to maintain 
protein homeostasis. The mechanism underlying the stabilizing effect of the acidic residues is 
not yet clear, and we do not know whether the presence of acidic residues merely counters 
the destabilizing impact of hydrophobic residues, or whether acidic residues can act 
independently to stabilize otherwise neutral sequences. This effect cannot simply be 
explained by the charge of the stabilizing residues, as enrichment for sequences rich in 
arginine was not observed in the stable bin. 
Sculpting of eukaryotic proteomes by C-terminal degrons 
How the C-terminal degrons are utilized to regulate protein stability remains to be 
determined. It is likely to vary on a case-by-case basis, as proteins bearing C-terminal 
degrons cannot be readily grouped into functional categories and the CRL adaptors that 
recognize C-terminal degrons are broadly expressed across human tissues. C-terminal 
degrons could be important for enforcing the stoichiometry of multi-subunit complexes, 
acting as constitutive degradation signals that are only exposed when a protein is not 
  
23 
correctly assembled with its binding partners. Indeed, N-end rule pathways have been shown 
to regulate subunit stoichiometry in this way (Shemorry et al., 2013), although we did not 
observe a significant enrichment for C-terminal degrons among proteins found in the 
CORUM database (Ruepp et al., 2010). The accessibility of C-terminal degrons might also be 
regulated by PTMs, thus linking them to signal transduction, or, as is the case for most N-end 
rule substrates (Tasaki et al., 2012), they could be generated from internal sequences 
following proteolysis. C-terminal degrons might also play a role in protein quality control, for 
example by degrading aberrant C-terminally extended proteins that result from failed 
translation termination and read through into the 3’ untranslated region (Arribere et al., 2016; 
Dunn et al., 2013). On a practical level, these data should guide the use of epitope tags, which 
might interfere with the endogenous regulation of protein stability by blocking the 
recognition of C-terminal degrons or adding new ones. The amino acid composition of the 
epitope tag may also in itself influence protein stability: the widely used FLAG epitope tag 
(DYKDDDDK), for example, is rich in aspartic acid and lysine residues, both of which could 
exert a stabilizing effect on the stability of the tagged protein (Figure 5B). 
Irrespective of their predominant physiological role, it is clear that the C-terminal 
degrons have played an important role in sculpting eukaryotic proteomes. The greater 
variability of amino acid abundances observed at the terminal position relative to internal 
positions suggests that some residues have particular functional significance when placed at 
the extreme C-terminus, this placing them under selective pressure. Evolutionary forces have 
reduced the number of proteins terminating in glycine among eukaryotes. In further support 
of the hypothesis that the selective pressure to reduce glycine at C-termini is due to the 
avoidance of CRL2 complexes that target glycine-end degrons, we found that the remaining 
glycine-end proteins are further depleted for residues at the -2 position that constitute 
favorable glycine-end degrons for CRL2-mediated degradation and enriched for residues that 
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disfavor CRL2-mediated degradation. This effect is not limited to glycine, however, as we 
also found that the human proteome is depleted of protein sequences containing other classes 
of C-terminal degron motifs.  
 
Conclusion 
 The GPS-peptidome technology represents a versatile tool for the identification of 
degron sequences. The ability to rapidly generate libraries of potential degrons, screen for 
degron activity, and define the degron sequences using scanning mutagenesis libraries is very 
powerful. This system has revealed that over half of all 90 amino acid peptides have degron 
activity, which has certain implications for de novo protein evolution. A detailed 
understanding of the specific sites on proteins that confer instability, coupled with genetics to 
uncover the cognate E3s involved, would open the way for the identification of drugs that 
inhibit these E3s for therapeutic modulation of the UPS in human disease. 
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FIGURE LEGENDS 
Figure 1. CRISPR screening combined with GPS profiling of a synthetic human 
peptidome identifies multiple CRL2 complexes targeting unstable peptides. 
(A) Overview of GPS-peptidome library construction and screening pipeline.  
(B) Stabilization of unstable GFP-peptide fusions in the Bin1 population upon treatment for 5 
h with 5 M of the proteasome inhibitor MG132, or 100 nM of the lysosomal inhibitor 
Bafilomycin A1 (BafA1), as assessed by FACS. 
(C to E) Isolation of CRL substrates. (C) Bin1 population was treated for 5 h with 1 M of 
MLN4924. Cells expressing stabilized GFP-peptide fusion peptides were then purified by 
FACS, and, after recovery, reanalyzed following MLN4924 treatment (D). Expression of DN 
Cullins for 24 h followed by FACS analysis (E, see also Figure S1D). 
(F) The heatmap represents the CRISPR screen MAGeCK scores for the indicated genes 
across each of the 17 individual clones. The full data for each clone is shown in Figure S2. 
(G) CRISPR-mediated ablation of the indicated genes in selected clones resulted in the 
stabilization of the GFP-peptide fusion proteins. An sgRNA targeting AAVS1 was used as a 
negative control.  
(H to J) KLHDC3 recognizes glycine-ended substrates. Six of the KLHDC3 substrates 
identified in the CRISPR screen terminated in glycine (H). For one example substrate (clone 
6), mutation of the terminal glycine stabilized the GFP-peptide fusion (I), as did repositioning 
the glycine by adding an additional 10 amino acids (-DNYNEPKANQ*) at the C-terminus 
(J).  
See also Figures S1 and S2. 
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Figure 2. A GPS-ORFeome screen identifies full-length glycine-ended proteins as CRL2 
substrates  
(A) Schematic representation of the GPS lentiviral vector. BC- barcode  
(B) Schematic representation of the GPS-ORFeome screen. 
(C) Example profiles for one unstable protein (CDK4) and one stable protein (HIST2H2AB) 
are shown. Each color series represents the distribution of sequencing reads for an individual 
barcode attached to the same GFP-ORF fusion. 
(D) Heatmap showing the relative proportions of each amino acid across the last five C-
terminal residues of the ORFs stabilized by MLN4924 compared to the whole GPS-
ORFeome library.  
(E) List of high confidence CRL substrates identified from the GPS-ORFeome screen that 
terminated with glycine.  
(F) Twelve candidate genes were selected at random from the list in (E), expressed with an 
N-terminal HA epitope tag in either wild-type (WT) or Cul2 knockout (KO) HEK-293T cells, 
and protein abundance assessed by immunoblot (IB).  
(G) For two example GPS-ORF substrates, treatment with 1 M MLN4924 for 5 h stabilized 
the wild-type proteins (top row), while mutation of the C-terminal glycine or the addition of 
one extra residue to the C-terminus resulted in peptide stabilization (bottom row). 
See also Figure S3. 
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Figure 3. C-terminal glycine correlates with protein instability and is depleted from 
eukaryotic proteomes. 
(A) C-terminal glycine correlates with instability: ORFs terminating in glycine are enriched 
in Bin1 and depleted from Bin5. Glycine at the terminal (-1) position is depicted in red, while 
glycine at all other positions in the last ten residues is shown in gray.  
(B) Normalized amino acid frequencies across the last ten residues of eukaryotic proteins.  
(C) Normalized frequency of glycine across the last ten residues of proteomes from the 
indicated taxa.  
(D) Amino acid proportions across the last ten positions of each proteome are shown. The 
data for each residue are normalized to the mean proportion across the last ten positions.  
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Figure 4. The CRL2 adaptors KLHDC2, KLHDC3 and KLHDC10 target distinct C-
terminal glycine degrons. 
(A) Schematic representation of the G-end GPS library screen. 
(B) Comparison of the amino acid frequencies observed at the -2 position preceding the C-
terminal glycine residue among KLHDC2, KLHDC3 or KLHDC10 substrates.  
(C) Consensus sequences for the C-terminal degrons recognised by KLHDC2, KLHDC3 or 
KLHDC10. 
(D) Saturation mutagenesis was performed for two Cul2KLHDC2 substrates (EPHB2 and 
PDGFC) and for two Cul2KLHDC3 substrates (EMID1 and CHGA). In each case, darker colors 
represent a greater degree of stabilization conferred by the mutation.  
(E) Summary of the C-terminal degrons recognized by KLHDC2, KLHDC3 and KLHDC10. 
(F) Comparison of the normalized frequency at the -2 position of the indicated “favored” (G, 
R, K, Q, W, P, A) or “disfavored” (D, E, V, I and L) amino acids for recognition by 
KLHDC2, KLHDC3 and KLHDC10. 
(G) Depletion of C-terminal glycine is specific to the proteomes of eukaryotes and eukaryotic 
viruses.  
See also Figure S4. 
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Figure 5. Global identification of C-terminal degrons through stability profiling of C-
terminal peptides.  
(A) Schematic representation of the C-termini GPS-peptidome screen. 
(B) Heatmaps showing the relative depletion (blue) or enrichment (red) of each amino acid 
across all positions of the 23-mer peptide in the unstable Bin1 population (left) versus the 
stable Bin4 population (right).  
(C) Greater numbers of acidic residues correlate with increased stability, while greater 
numbers of bulky aromatic residues correlate with instability.  
(D) For all possible combinations of di-peptide motifs, the mean difference in stability 
between peptides containing the motif at the extreme C-terminus was compared to peptides 
containing the motif at an internal position in the 23-mer peptide (see Methods).  
(E) Identification of common classes of potential degron motifs among the top 100 motifs 
predicted to be most destabilizing specifically when located at the C-terminus.  
(F) Boxplots showing the distribution of Protein Stability Indices (PSI) for all peptides 
harboring the indicated classes of motif internally within the 23-mer peptide (gray boxes) or 
at the C-terminus (colored boxes). 
(G) Heatmap showing the relative enrichment (red) or depletion (blue) of amino acids among 
the C-terminal tails of APPBP2 substrates relative to the whole pool of unstable peptides in 
the GPS-peptidome library.  
(H) Logoplots showing the consensus C-terminal amino acid sequences among APPBP2 
substrates containing glycine at -2 (top) or -3 (bottom) position.  
(I) Summary of the C-terminal degron recognized by APPBP2. 
See also Figures S5, S6 and S7. 
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Figure 6. Identification of additional classes of C-terminal degrons recognized by CRL2 
and CRL4 complexes. 
(A to C) Heatmaps displaying the relative depletion (blue) or enrichment (red) of each amino 
acid across the last five C-terminal residues of peptide substrates stabilized following 
treatment with (A) MLN4924, (B) DN Cul2 or (C) DN Cul4, compared in each case to the 
whole C-terminal GPS-peptidome library.  
(D and E) Cells expressing GPS constructs in which GFP is fused to the last 23 residues of 
(D) CDK5R1, (E) MAGEA3 or NPPB were analyzed either as wild-type, with mutation of 
the key C-terminal residues or with addition of amino acids (-KASTN*) at the C-terminus, 
with or without the indicated inhibitor or expression of DN Cullin as indicated. 
(F) Heatmap representing the degree of enrichment of the indicated genes in the CRIPSR 
screen as determined by MAGeCK comparing the sorted cells to the unselected populations. 
(G) Summary of the C-terminal degrons recognized by FEM1A-C, DCAF12 and TRPC4AP. 
(H) HEK-293T or A375 cells were treated with 1 M MLN4924 for 8h and protein 
abundance assessed by immunoblot (IB).  
(I) HEK-293T cells (TSPYL1, p14ARF or PTOV1 immunoblots) or A375 cells (CCT5 or 
MAGEA3 immunoblot) were transduced with Cas9 and sgRNAs targeting the indicated 
genes and protein abundance was assessed by immunoblot 7 days later.  
(J) HEK-293T cells expressing GFP fused to N-Myc C-terminal 23 residues were transduced 
with Cas9 and two independent sgRNAs targeting TRPC4AP and analyzed 7 days later by 
FACS.  
(K) Mutation of the critical arginine or deletion of the last three residues stabilized the GFP-
fusion protein as measured by FACS.  
See also Figures S6 and S7. 
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Figure 7. Recognition of C-terminal degrons is a general property of E3s that has 
shaped the human proteome.  
(A) Of the top 100 predicted destabilizing C-terminal motifs (Figure 5), 58 are enriched 
among the pool of CRL substrates while 42 are not.  
(B) Boxplots showing the distribution of PSI for all peptides harboring the indicated classes 
of motif internally within the 23-mer peptide (gray boxes) or at the C-terminus (colored 
boxes). 
(C) Cells expressing GPS constructs in which the C-terminal 23 residues of the indicated 
genes comprising representative non-CRL degrons were fused to GFP. These degrons were 
analyzed either as wild-type, with mutation of the key C-terminal residues, or with addition 
of amino acids (-KASTN*) at the C-terminus as indicated, with or without the indicated 
inhibitors.  
(D) Summary of the non-CRL C-terminal degrons. 
(E) Normalized amino acid frequency of the indicated residue(s) in the human proteome, 
showing the degree of depletion at the degron position (colored bars) versus the mean 
normalized frequency across all other positions in the C-terminal tail (gray bars). (*P<0.05, 
**P<0.01, ***P<0.001; Fisher’s exact test).  
(F) Heatmap showing the significance of the depletion of each residue across the last five C-
terminal residues of the human proteome.  
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SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Figure 1. Isolating CRL substrates using a synthetic human peptidome, 
Related to Figure 1.  
(A and B) Performance of the GPS-peptidome library in HEK-293T cells. (A) Flow 
cytometry analysis of the starting library (pink line) compared to the four sorted populations 
(filled histograms). (B) Comparison of the relative stability of the Bin1 population, which 
contains the most unstable GFP-peptide fusions, compared to GFP alone. 
(C and D) Isolation of CRL substrates using the Cullin inhibitor MLN4924. (C) The Bin1 
population was treated with either MLN4924 or DMSO and analyzed by flow cytometry. 
Approximately 8% of the GFP-peptide fusions were stabilized by MLN4924, and these cells 
were isolated by FACS. (D) The Bin1 MLN4924-responsive cells from (C) were transduced 
with lentiviruses encoding dominant-negative (DN) Cullins and analyzed by flow cytometry 
24 h later. 
(E-H) KLHDC3 physically associates with its peptide substrates. (E) HA-tagged KLHDC3 
or METAP2 (control) expression constructs were transiently transfected into Clone 3 cells 
which express an unstable GFP-peptide fusion peptide targeted by Cul2KLHDC3. KLHDC3 was 
immunoprecipitated with anti-HA antibodies and co-immunoprecipitating proteins identified 
by immunoblot using the indicated antibodies. (F) HEK-293T cells stably expressing HA-
tagged KLHDC3 were transfected with expression constructs encoding the GFP-peptide 
fusion from Clone 6 (a Cul2KLHDC3 substrate) or Clone 14 (a Cul2FEM1A/C substrate) and 
analysed as in (E). (G) KLHDC3 associates with a GFP-peptide substrate generated in vitro. 
The GFP-peptide expressed by Clone 6 or GFP alone were in vitro transcribed and translated 
using E. coli extracts and immobilized on magnetic beads coated with anti-GFP antibodies. 
The beads were then incubated with extracts from cells stably expressing HA-tagged 
KLHDC3 and binding assessed by immunoblot.  
(H and I) A C-terminal glycine residue is required for Cul2KLHDC3 mediated degradation. In 
addition to the data presented in Figures 1I and 1J, data for a further clone (Clone 5) is shown 
here. (H) Stabilization of the GFP-peptide fusion was observed by flow cytometry upon 
mutation of the C-terminal glycine to alanine (G/A) or, to a greater extent, to aspartic acid 
(G/D). (I) Stabilization was also observed upon the addition of an extra 10 residues (-
DNYNEPKANQ*) to the C-terminus.  
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Supplementary Figure 2. CRISPR/Cas9 genetic screens identify CRL2 BC box adaptors 
responsible for the degradation of unstable peptides, Related to Figure 1.  
(A) Schematic representation of the screen. Seventeen clones expressing GFP-peptide fusions 
stabilized by expression of DN Cul2 and Cul5 were selected at random and transduced with a 
CRISPR library targeting 69 CRL2/5 adaptors. The population of cells in which the GFP-
peptide fusion was stabilized were then isolated by FACS and the enriched sgRNAs 
identified by Illumina sequencing.  
(B) CRISPR screen results for each of the 17 clones, as determined using the MAGeCK 
algorithm (7).  
 
 
Supplementary Figure 3. A GPS-ORFeome screen measures the stability of the human 
proteome and identifies full-length CRL substrates, Related to Figure 2. 
(A) Illumina sequencing of the 3’ ‘barcode’ cassette enables effective identification of the 
upstream ORF. Example profiles from each of the five sorted populations are shown; each 
color series represents the distribution of sequencing reads for a different barcode attached to 
the same GFP-ORF fusion. In each case, highly similar distributions are observed between 
the different barcodes.  
(B) GFP-fusion proteins are predominantly degraded by proteasomes. Each of the five 
populations was treated with the proteasome inhibitor MG132 (5 μM for 5 h) and 
stabilization of the GFP-fusion proteins was monitored by flow cytometry.  
(C and D) Sorting strategy used to isolate CRL substrates from the GPS-ORFeome library. 
(C) Populations of cells expressing unstable GFP-ORF fusion proteins were treated for 5 h 
with 1 M MLN4924 and the stabilized protein isolated by FACS. After recovery in the 
absence of the inhibitor, cells in which the GFP-fusion proteins were once again efficiently 
degraded were recovered in a second sort. Sorting plots for Bin1 are shown; a similar 
procedure was also carried out using Bin2 and Bin3. (D) The final populations of MLN4924-
responsive substrates recovered after sorting were reanalysed in the presence of 1 M 
MLN4924.  
(E) CRL2 is responsible for degrading the majority of unstable GFP-ORF fusion proteins. 
The MLN4924-responsive populations isolated from Bin1 and Bin2 were transduced with 
lentiviral vectors encoding dominant-negative (DN) versions of the indicated Cullins, and the 
proportion of substrates stabilized was assessed by flow cytometry 24 h later. 
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Supplementary Figure 4. The CRL2 adaptors KLHDC2, KLHDC3 and KLHDC10 
target glycine-ended substrates for proteasomal degradation, Related to Figure 4. 
(A and B) Defining the glycine-end degron recognized by KLHDC3. (A) Alanine scanning 
mutagenesis was performed across five Cul2KLHDC3 GFP-peptide substrates, while (B) 
saturation mutagenesis was performed for one substrate (Clone 8). In each case, the darker 
the color the greater the degree of stabilization conferred by the mutation.  
(C) Isolation of Cul2KLHDC3 substrates. Schematic representation of the experiment. The 
MLN4924-responsive pool of unstable GFP-peptide fusions was transduced with two 
independent sgRNAs targeting KLHDC3, and cells in which the GFP-peptide fusion were 
stabilized were isolated by FACS. 
(D and E) Sequence analysis of KLHDC3 substrates. (D) Heatmap displaying the relative 
enrichment (red) or depletion (blue) of amino acids among the C-terminal tails of KLHDC3 
substrates relative to the whole pool of unstable peptides. The vast majority of KLHDC3 
substrates have a glycine (G) residue at the terminal position, although some substrates 
bearing a terminal alanine (A) were also identified. An enrichment for arginine (R), lysine 
(K) and glutamine (Q) was observed at the penultimate (-2) position. (E) Logoplot 
representing the consensus C-terminal sequence of all KLHDC3 substrates identified from 
the GPS-peptidome library 
(F-H) Identification of glycine-ended peptide CRL substrates using the G-end GPS library. 
(F) The identity of the penultimate amino acid affects the stability of glycine-ended proteins. 
The normalized frequency of the indicated amino acids at the penultimate (-2) position 
relative to the overall frequency of amino acids in the G-end peptide library is shown for each 
of the three bins. (G) Isolation of CRL substrates. The Bin1 population of cells from the G-
end GPS-peptidome library was treated with MLN494 for 5 hours and then analyzed by flow 
cytometry; approximately 11% of cells expressed GFP-peptide fusions that were stabilized by 
MLN4924, and these cells were isolated by FACS. (H) Isolation of KLHDC2, KLHDC3 and 
KLHDC10 substrates. The MLN4924-responsive sorted population from (G) was transduced 
with Cas9 and sgRNAs targeting either KLHDC2, KLHDC3, KLHDC10 or AAVS1 as a 
negative control and the indicated populations of cells exhibiting stabilization of the GFP-
peptide fusion were isolated by FACS. 
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Supplementary Figure 5. Cul2APPBP2 targets substrates bearing RxxG motifs near their 
C-terminus for proteasomal degradation, Related to Figure 5. 
(A) Schematic representation of the experiment designed to identify the degron recognized by 
Cul2APPBP2. The MLN4924-responsive pool of GFP-peptide fusions of the GPS-peptidome 
library was transduced with two independent sgRNAs targeting APPBP2, and cells in which 
the GFP-peptide fusion was stabilized were isolated by FACS.  
(B and C) APPBP2 recognizes C-terminal RxxG motifs. (B) Knockout of APPBP2 stabilizes 
substrates bearing C-terminal RxxG motifs. HEK-293T cells were transduced with GPS 
constructs expressing GFP fused to either full-length PXN, peptides corresponding to the C-
terminal tails of PIK3C2B and ASCC3, or the peptide sequence of Clone 1 (Figure 1F), and 
then subsequently transduced with Cas9 and two independent sgRNAs targeting APPBP2 and 
analyzed 7 days later by flow cytometry. The last 6 amino acids of each GFP-fusion protein 
are shown with the RxxG motifs underlined. (C) Alteration or repositioning of the RxxG 
motif stabilizes APPBP2 substrates. Mutation of the RxxG motif (blue line) or repositioning 
of the RxxG motif through the addition of extra residues (-DNYNEPKVANQ*) at the C-
terminus (red line) resulted in the stabilization of the GFP-fusion proteins, as measured by 
flow cytometry. 
(D) Defining the RxxG degron recognized by APPBP2. Saturation mutagenesis was 
performed for two substrates (left- XP_211896, right- peptide #35 (Table S11)). In each case, 
the darker the color the greater the degree of stabilization conferred by the mutation. 
  
 
Supplementary Figure 6. Identifying degrons at the C-termini of human proteins 
targeted by CRLs, Related to Figure 5.  
(A) Performance of the C-terminal GPS library in HEK-293T cells. A GPS library in which 
the last 23 residues of all human proteins were fused to GFP was expressed in HEK-293T 
cells and sorted into four bins based on the stability of the GFP-peptide fusion protein.  
(B) Isolation of C-terminal peptides targeted by CRLs. To purify CRL substrates, the Bin1 
and Bin2 populations from the C-terminal GPS-peptidome library were treated with 
MLN4924 and the cells expressing stabilized GFP-peptide fusions isolated by FACS. 
(C and D) Composition of C-terminal motifs targeted by CRLs. The heatmaps display the 
relative depletion (blue) or enrichment (red) of each amino acid across the last five C-
terminal residues of peptide substrates stabilized by MLN4924 that contain a glutamic acid 
residue at either the -1 or -2 position (C) or an arginine residue at the -3 position (D). This 
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revealed that the C-terminal acidic residues are found together as a twin glutamic acid degron 
motif (-EE end), while arginine at the -3 position (R at -3 motif) is frequently paired with 
terminal histidine, proline, aspartic acid or glutamine residues. 
(E) CRL2 and CRL4 complexes recognize C-terminal degrons. The MLN4924-reponsive 
populations from (B) were treated with MLN4924 or transduced with constructs encoding 
dominant-negative (DN) Cul2, Cul4A or Cul4B; the cells in which the GFP-peptide fusions 
were stabilized were again isolated by FACS. 
 
 
Supplementary Figure 7. CRISPR screens identify the CRL adaptors targeting 
additional classes of C-terminal degrons, Related to Figure 6. 
(A and B) Validation of CRL-mediated degradation through R-end, EE-end and R at -3 C-
terminal degron motifs. Additional validation data is presented here as in Figures 6D and 6E, 
using a different example peptide sequence in each case. (A) A C-terminal arginine can act as 
a degron for CRL2-mediated degradation. A GPS construct in which the last 23 residues of 
SIL1 was fused to GFP was used as an example arginine-end degron. Wild-type GFP-SIL1 
peptide is stabilized after 5 h treatment with either MLN4924 or MG132 (top); whereas 
mutation (middle) or deletion (bottom) of the terminal arginine abrogated CRL-mediated 
degradation and stabilized the GFP-peptide fusion. (B) CRL4-mediated recognition of C-
terminal degrons. Attaching the last 23 residues of MYH3 (ending –EE) or MSRB2 (ending –
RxH) to GFP destabilizes the fusion protein; this can be rescued upon exogenous expression 
of DN Cul4 (top). In each case alanine mutagenesis of the terminal motifs (–EE to –AA and –
RxH to –AxA) abolished CRL-mediated degradation; however, the mutant peptides remained 
unstable and presumably now served as substrates for other E3s (middle). Addition of extra 
residues at the C-terminus also resulted in stabilization (bottom).  
(C) Defining the degrons recognized by DACF12 or TRPC4AP. Saturation mutagenesis was 
performed for one substrate each. In each case, the darker the color the greater the degree of 
stabilization conferred by the mutation. 
(D-E) CRISPR/Cas9-mediated genetic screens identify additional CRL2 and CRL4 adaptors 
responsible for C-terminal recognition. (D) Overview of the CRISPR screening strategy. 
Example 23-mer C-terminal peptides ending in –R (CDK5R1 and SIL1), -EE (MAGEA3 and 
SAT1) or containing an R at -3 motif (MGAT2, MSRB2 and NPPB) were fused to GFP and 
expressed in HEK-293T cells, and then transduced with a CRISPR sgRNA library targeting 
either CRL2 adaptors (-R end peptides) or CRL4 adaptors (-EE end and R-3 motif peptides). 
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The population of cells in which the GFP-peptide fusion was stabilized were then isolated by 
FACS and the enriched sgRNAs identified by Illumina sequencing. (E) CRISPR screen 
results for each of the 7 clones, as determined using the MAGeCK algorithm, together with 
the amino acid sequences of the last 10 residues of each construct. 
(F) Regulation of protein stability through the recognition of terminal degrons. As at the N-
terminus, an array of E3s identified in this study target proteins bearing C-terminal degron 
motifs for proteasomal degradation. (B, Elongin B; C, Elongin C). 
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STAR Methods  
CONTACT FOR REAGENT AND RESOURCE SHARING  
Further information and request for reagents may be directed to the corresponding author 
Stephen J. Elledge (selledge@genetics.med.harvard.edu).  
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS  
Cell Lines 
HEK-293T (ATCC® CRL-3216™) and A375 (a gift from C. Novina) cells were maintained 
in Dulbecco’s Modified Eagle’s Medium (DMEM) (Life Technologies) supplemented with 
10% fetal bovine serum (HyClone) and penicillin/streptomycin (Thermo Fisher Scientific). 
 
METHOD DETAILS 
Transfection and lentivirus production.  
Lentiviral stocks were generated through the transfection of HEK-293T cells with the 
lentiviral transfer vector plus plasmid encoding Gag-Pol, Rev, Tat and VSV-G using either 
TransIT-293 transfection reagent (Mirus) or PolyJet In Vitro DNA Transfection Reagent 
(SignaGen Laboratories) as recommended by the manufacturer. Lentiviral supernatants were 
collected 48 h later, passed through a 0.45 μm filter, and applied to target cells in the 
presence of 8 μg/ml hexadimethrine bromide (Polybrene, Sigma-Aldrich).  
 
Inhibitors, antibodies and plasmids.  
The proteasome inhibitor MG132 was obtained from R&D Systems and Bortezomib from 
ApexBio. The lysosomal inhibitor Bafilomycin A1 was obtained from Enzo Life Science, and 
the pan-Cullin inhibitor MLN4924 was obtained from Active Biochem. Primary antibodies 
used in the study were mouse anti-Vinculin (Sigma-Aldrich, V9131), mouse anti-p14ARF 
(Cell Signaling, 2407), rabbit anti-MAGEA3 (Abgent, AP6165a), rabbit anti-PTOV1 (abcam, 
  
42 
ab81173), rabbit anti-TSPYL1 (abcam, ab95943), rabbit anti-CCT5 (Bethyl, A303-480A), rat 
anti-HA-peroxidase (Sigma-Aldrich, 1201381900) and rabbit anti-GFP (Abcam, ab290). 
Secondary antibodies were obtained from Jackson ImmunoResearch Laboratories.  
Plasmid vectors encoding cDNAs for SNURF, TIAF1, RBM38, DLX1, ZMAT5, 
TCAP, RSDA1, CHCHD3, STRADA, SMOC2, EMID1, IRX6, KLHDC3 and METAP2 
were obtained from the Ultimate ORF Clone collection (Thermo Fisher Scientific) and were 
subcloned into the lentiviral pHAGE-Flag-HA or pHAGE-GPS Gateway Destination vector 
via an LR recombination reaction (Thermo Fisher Scientific). Dominant-negative Cullin 
constructs were a kind gift from W. Harper. For individual CRISPR/Cas9-mediated gene-
disruption experiments, sgRNAs were cloned into lentiCRISPR v2 (Addgene #52961, 
deposited by Feng Zhang) as described (Sanjana et al., 2014). The nucleotide sequences of 
the sgRNAs used were: 
sg1-APPBP2: GATGTAGTTGTCCACGACAG 
sg2-APPBP2: GGATGTTCTCGGGCAAGGAG 
sg1-KLHDC2: GGCCACATGTTCGTCTGGGG  
sg2-KLHDC2: GAGCTTCCTGACATAGAAGG  
sg1-KLHDC3: GCGGTGGACAGTGCACCTGG  
sg2-KLHDC3: GGGGCAGCCCTGCACGCTGG  
sg1-KLHDC10: GCCTCCGCCACCAGCGCCGG 
sg2-KLHDC10: GGGCGCCTCCTCCCCTCCGG 
sgFEM1A: GGCGCGAGCGTGGAGGCCGG  
sgFEM1C: GTCAAGGTGCCCATACCTGG 
sgCUL2: GTTGACGACAATAAAAGCCG 
sgDACF12: GCAACTTCCCAGTCTCCTGA 
sg1: TRPC4AP: GATAGCCTCCATGGAGAGAAG 
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 sg2: TRPC4AP: GAGGCCTACGATCTCTATCCG  
sgAAVS1: GGGGCCACTAGGGACAGGAT 
 
Flow cytometry.  
HEK-293T cells were detached with trypsin, washed once with PBS, and then analyzed on a 
BD LSRII instrument (Becton Dickinson). Flow cytometry data was collected using BD 
FACS Diva software (Becton Dickinson) and analyzed using FlowJo software. Cell sorting 
was performed on either a BD FACSAria II (Becton Dickinson) or a MoFlo Astrios 
(Beckman Coulter) instrument. 
 
 
Generation of GPS libraries.  
GPS-peptidome library. Protein coding sequences (CDS) for all human genes were 
downloaded from RefSeq database and the longest isoform of each gene used for 
oligonucleotide design. The protein sequences were first encoded as DNA bases using 
random codons, which were then divided into 270 bp regions tiling across the entire CDS 
with 135 bp overlaps between neighboring oligonucleotides and with flanking 15 bp primers 
as described (Xu et al., 2016). The DNA was amplified by PCR using specific primers that 
included attB sites to allow the products to be cloned into pDONR223 via a Gateway BP 
recombination reaction and subsequently into the the lentiviral GPS vector pHAGE-GPS3.0-
DEST via an LR recombination reaction (Thermo Fisher Scientific). At least 100-fold 
representation of the library was maintained at each cloning step. 
 
Barcoded GPS-ORFeome library. A three step cloning strategy was used to generate the 
barcoded GPS-ORFeome library. First, random 24-mer oligonucleotides (IDT) were 
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amplified by PCR and cloned into the lentiviral Gateway destination vector pHAGE-CMV-
DEST-PGKpuro between the SbfI and XhoI sites to generate a barcoded vector library 
(pHAGE-CMV-DEST-PGKpuro 3’BC). The pool of barcoded vectors was then linearized 
with BstZ17I (NEB), gel purified (Qiagen QIAEX II Gel Extraction Kit), and subjected to a 
Gateway LR recombination reaction (Thermo Fisher Scientific) using entry clones from the 
Ultimate ORF collection assembled into six pools containing approximately 3000 ORFs each. 
ORF-barcode pairs were subsequently mapped by linearizing the plasmids with I-SceI, 
followed by fragmentation (NEBNext dsDNA Fragmentase), end repair, dA tailing and 
adaptor ligation (NEBNext DNA Library Prep kit). After the ligation step, fragments ranging 
from 300-600 bp were purified from an agarose gel (Qiagen QIAEX II Gel Extraction Kit) 
and two rounds of PCR were performed to add the appropriate adaptor sequences for paired-
end Illumina sequencing; the final pHAGE-CMV-ORF-PGKpuro 3’BC library had an 
average complexity of approximately 5 barcodes per ORF. Lastly, the CMV promoter was 
replaced with a CMV-DsRed-IRES-GFP cassette using PI-SceI and I-Ppol sites to generate 
the final barcoded GPS-ORFeome expression library. 
  
 GPS G-end library. Human protein-coding sequences were downloaded from the 
GENCODE database. In total, 2245 unique sequences encoding a protein terminating in 
glycine followed by a stop codon were selected for oligonucleotide design. The terminal 168 
bp of each sequence together with common flanking PCR primer sites were synthesized as an 
oligonucleotide library by Twist Bioscience. The pool of oligonucleotides were amplified by 
PCR and inserted into pHAGE-GPS3.0-DEST via Gateway BP and LR recombination 
reactions.  
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  GPS C-terminal 23-mer library. Protein-coding sequences for all human proteins 
were downloaded from the RefSeq database and the terminal 23 amino acids of each selected 
for oligonucleotide design (27,030 sequences in total). Protein sequences were encoded as 
DNA bases using random codons, common 15 bp flanking primer sequences were added at 
each end and the oligonucleotide library was synthesized by Agilent. The pool of 
oligonucleotides were amplified by PCR and inserted into pHAGE-GPS3.0-DEST via 
Gateway BP and LR recombination reactions.  
 
 Mutagenesis libraries. Scanning mutagenesis was performed for five clones (Clones 3, 
5, 6, 7 and 8). For each of the five peptide sequences, each amino acid in turn was mutated to 
alanine (encoded by GCT), or, if the original residue was glycine, to arginine (encoded by 
CGT). Saturation mutagenesis was performed on a single clone from the original 90-mer 
peptidome (Clone 8), as well as on selected C23-mer peptides bearing the different identified 
degrons. For each amino acid in the peptide sequence, a set of mutant sequences were 
generated in which the residue was mutated in turn to all of the other 19 possible amino acids. 
The codons used for the amino acids substitutions were: A: GCT, C: TGC, D: GAC, E: GAA, 
F: TTC, G: GGC, H: CAC, I: ATC, K: AAA, L: CTC, M: ATG, N: AAC, P: CCT, Q: CAA, 
R: CGC, S: TCT, T: ACT, V: GTC, W: TGG, Y: TAC. Finally, common 15 bp flanking 
primer sequences were added at each end and the oligonucleotide library was synthesized by 
Twist. The pool of oligonucleotides were amplified by PCR and inserted into pHAGE-
GPS3.0-DEST via Gateway BP and LR recombination reactions.  
 
GPS screens.  
GPS libraries were packaged into lentiviral particles. HEK-293T cells were transduced at low 
multiplicity of infection (MOI) (approximately 20% DsRed+ cells) at sufficient scale to 
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maintain ~500-fold coverage of the library. Untransduced cells were eliminated through 3 
days of puromycin selection (1.5 µg/ml) commencing 48 h post transduction. The surviving 
cells were then expanded and sorted 7-9 days post-transduction into either 3 bins (GPS G-end 
library, scanning alanine mutagenesis library and the saturation mutagenesis library), 4 bins 
(GPS-peptidome library, C-terminal 23-mer GPS-peptidome library) or 5 bins (GPS-
ORFeome library), based on the GFP/DsRed ratio.  
Genomic DNA was extracted from each of the pools (Qiagen Gentra Puregene Cell Kit). 
The GFP-fusion peptides (or associated ORF barcodes in the case of the GPS-ORFeome 
screen) were amplified by PCR with Q5 Hot Start Polymerase (NEB) using PCR primers 
annealing to common regions of the lentiviral vectors; overall the reactions contained a total 
mass of DNA equivalent to the mass of genomic DNA from cells representing 500-fold 
coverage of the library. All of the PCR products were pooled, purified using a spin column 
(Qiagen PCR purification kit), and then 200 ng of the purified product used as a template for 
a second PCR reaction using primers to add the Illumina P5 sequence and a ‘stagger’ region 
of 1-7 bp at the 5’end and an Illumina index and the P7 sequence at the 3’ end (Meyer and 
Kircher, 2010). Samples were then further purified on an agarose gel (QiaQuick Gel 
Extraction kit), pooled, and sequenced on either an Illumina HiSeq2500, NextSeq or MiSeq 
instrument.  
 
CRISPR screens.  
For the initial CRISPR screens performed on the 17 clones derived from the original GPS-
peptidome screen (Figure 1F), a custom sgRNA library was designed targeting 69 CRL2/5 
adaptors at a depth of 12 sgRNAs per gene. For the CRISPR screens performed using the C-
terminal 23-mer GFP-peptide fusion GPS constructs (Figure 6F), two further custom sgRNA 
libraries were designed targeting 11 CRL components and either 109 CRL2/5 adaptors or 62 
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CRL4 adaptors at a depth of 6 sgRNAs per gene. In each case, the sgRNA sequences were 
flanked with BbsI restriction sites and common primer sites and synthesized as 
oligonucleotides by Agilent or Twist Bioscience. The resulting oligonucleotide pool was 
amplified by PCR, and the products purified on a spin column (Qiagen PCR purification kit) 
and digested with BbsI (NEB). Following ethanol precipitation, DNA fragments were 
separated on a 10% TBE PAGE gel (Thermo Fisher Scientific) and the 28 bp band 
corresponding to the sgRNAs excised. The DNA was extracted by crushing the gel slice into 
small pieces followed by soaking in TE buffer for 2 h at room temperature. Following a final 
ethanol precipitation step, the sgRNA fragment was ligated into the lentiCRISPR v2 
(Addgene plasmid #52961) vector that had previously been digested with BsmBI (NEB) and 
purified on an agarose gel (Qiagen QIAEX II gel extraction kit). 
The sgRNA library was packaged into lentiviral particles which were used to transduce 
HEK-293T expressing unstable GFP-peptide fusions at a MOI ~0.3 at sufficient scale to 
maintain ~1000-fold representation of the library. Eight days later the top 5% of the 
population based on GFP/DsRed ratio were isolated by FACS. For each clone, genomic DNA 
was extracted from both the sorted cells and the unsorted library as a reference. sgRNA 
sequences in both populations were amplified by PCR and sgRNA abundance quantified by 
Illumina sequencing.  
 
Immunoprecipitation and immunoblotting.  
Immunoprecipitation of HA-tagged proteins was performed from HEK-293T cells growing in 
10 cm plates 24 h after transfection and 4 h after treatment with 5 μM MG132. Cells were 
lysed in ice-cold lysis buffer (50 mM Tris, 100 mM NaCl, 0.5% NP-40, pH 7.5 supplemented 
with EDTA-free protease inhibitor tablet and Phos-Stop phosphatase inhibitor tablet (Roche)) 
for 25 min at 4°C. Lysates were clarified by centrifugation (20,000 x g, 15 min, 4°C) and 
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nuclear pellets were resuspended in lysis buffer, sonicated briefly, and re-clarified. HA 
agarose beads (Sigma-Aldrich) were added to the combined whole cell extracts and the 
samples incubated with rotation for 2 h at 4°C. Beads with bound immune complexes were 
washed 4 times with lysis buffer and twice with TBS (25 mM Tris, 100 mM NaCl), followed 
by elution with 100 μg/ml HA peptide (Sigma-Aldrich) for 30 min at 30°C. SDS-PAGE 
sample buffer was then added to the eluted sample and boiled. Proteins were separated by 
SDS-PAGE, transferred to a nitroceullose membrane, blocked in 10% Nonfat Dry Milk in 
PBS + 0.1% Tween-20 (PBS-T), and then probed with primary antibody overnight at 4°C. 
Following three washes with PBS-T, the membrane was incubated with secondary antibody 
for 1 h at room temperature, washed a further three times in PBS-T, incubated with Western 
Lightning Plus ECL (Perkin Elmer) for 5 min and reactive bands visualized using HyBlot CL 
film (Denville Scientific).  
GFP immunoprecipitations were performed in a similar way, using GFP-Trap®_MA 
magnetic agarose beads (ChromoTek GmbH) to capture GFP-fusion proteins followed by 
elution with 2M Glycine for 1 min. In vitro transcription and translation was performed using 
the PURExpress In Vitro Protein Synthesis Kit (NEB) as recommended by the manufacturer. 
Plasmids (500 ng) encoding GFP alone or a GFP-peptide fusion were incubated in 25 μl 
reaction mix, supplemented with RNAse inhibitor, for 3 h at 37°C. All of the material was 
then bound to GFP-Trap®_MA magnetic beads (ChromoTek GmbH) for 2 h at 4°C in 500 μl 
lysis buffer. 
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QUANTIFICATION AND STATISTICAL ANALYSIS  
CRISPR screens.  
Illumina reads were first trimmed of constant regions derived from the backbone of 
lentiCRISPR v2 expression vector using Cutadapt (Martin, 2011). Count tables were 
generated from the remaining variable sgRNA sequences using Bowtie 2 (Langmead and 
Salzberg, 2012; Langmead et al., 2009). The Model-based Analysis of Genome-wide 
CRISPR/Cas9 Knockout (MAGeCK) method (Li et al., 2014) was used to rank the 
performance of individual genes targeted by multiple sgRNAs enriched in the selected cells 
versus the unsorted populations. The full MAGeCK results for each screen are presented 
either in Table S1 or Table S13. 
 
GPS-ORFeome screen.  
Illumina reads were trimmed of constant regions derived from the backbone of the GPS 
expression vector using Cutadapt. The number of occurrences of each of the 24 nt barcode 
sequences that remained was then quantified using Bowtie 2. In the majority of cases 
barcodes could be uniquely assigned to individual ORFs; however in cases where a barcode 
could not distinguish between multiple isoforms of the same gene (indicated by a lower case 
‘ioh’ identifier in Table S3), read counts were assigned to all isoforms of that gene. After 
correcting for sequencing depth, the stability of each individual barcoded ORF was assessed 
based either simply on the bin containing the greatest number of reads (Modal Bin) or using 
the protein stability index (PSI) metric, given by the sum of multiplying the proportion of 
reads in each bin by the Bin number (1-5 in this case), thus yielding a stability score between 
1 (maximally unstable) and 5 (maximally unstable):   
PSI = ∑ 𝑅𝑅 ∗𝑅5𝑅=1     
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(where i represents the Bin number and Ri represents the proportion of the Illumina reads 
present for an ORF in that given subpopulation i). 
Two methods were used to identify CRL substrates. First, the mean of the counts for 
each barcode was used to collapse the data for each ORF, and then ORFs were categorized as 
CRL substrates if the read counts were >5-fold enriched in either of the MLN4924-
responsive populations derived from Bin1, Bin2 or Bin3 compared to the corresponding 
starting populations. Additionally, to generate a set of CRL substrates at higher stringency, 
MAGeCK was used to identify barcoded ORFs significantly enriched in the MLN4924-
responsive populations versus the corresponding starting populations. For the heatmap shown 
in Figure 2D, the intensity of the colors represent the depletion (blue) or enrichment (red) of 
each amino acid across the last five C-terminal residues comparing the pool of CRL 
substrates to all ORF detected in the GPS-ORFeome library. For the scatterplot in Figure 3A 
ORFs were assigned to bins using the Modal Bin stability metric, and for each pool of ORFs 
the relative frequency of glycine at each position in the last ten C-terminal residues was 
compared to the frequency of glycine at the corresponding position among all ORFs detected 
in the GPS-ORFeome library.      
 
Proteome composition analysis.  
Reviewed protein sequences were downloaded from the Swiss-Prot database. For each 
position across the last 10 C-terminal residues, the total abundance of each amino acid was 
quantified, expressed as a proportion of the total number of protein sequences, and then 
normalized to the mean proportion observed across the last 10 C-terminal residues. For the 
graph shown in Figure 4G, we further categorized glycine residues occurring within the last 
10 amino acids as either ‘favored’ for CRL2-mediated degradation if they were preceded by 
G, R, K, Q, A, P or W, or ‘disfavored’ if preceded by D, E, V I or L. The abundance of 
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Gfavored and Gdisfavored across the last 10 C-terminal amino acids was then quantified and 
normalized as above, and the normalized frequency of each at the extreme C-terminal residue 
is plotted.       
Mutagenesis GPS experiments.  
Sequencing reads were mapped to peptidome library using BLAT (Kent, 2002) and only 
reads perfectly matching the reference sequence were considered.  After normalization for 
sequencing depth, the PSI stability metric was calculated as above for each peptide (yielding 
a value between 1 and 3 in this case). The heatmaps displayed in Figures 4A and 4B were 
generated using the Seaborn visualization library for Python (https://seaborn.pydata.org/) and 
illustrate the difference between the PSI for each individual mutant peptide and the median 
PSI of all peptides; the darker the red color, the greater the stabilizing effect of the mutation. 
The full data for all mutant peptides is detailed in Tables S4 and S5.  
 
Defining the degrons for KLHDC3 and APPBP2 from GPS-peptidome substrates. 
Sequencing reads were mapped to peptidome library using BLAT. Peptides were classified as 
substrates if, with both of the two independent KLHDC3 or APPBP2 sgRNAs, they exhibited 
>2-fold enrichment over the unsorted starting population, >2-fold enrichment over the control 
sorted populations (those transduced with either Cas9 alone or Cas9 plus the sgAAVS1 
control guide), and were identified with at least 100 reads in the sorted sample (Table S6 and 
S11). The logoplots shown in Figures 5H and S4C were generated by WebLogo3 (Crooks et 
al., 2004); as a reference, the expected composition of the sequences was set to reflect the 
relative frequency of amino acids residues across the human proteome.   
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G-end GPS-peptidome screen.  
Illumina MiSeq reads were trimmed of common flanking sequences using Cutadapt and 
Bowtie 2 was used to count the occurrences of the 168 nt variable regions encoding the 56-
mer peptides. Only reads perfectly matching the reference sequence were considered. The 
PSI was calculated as described previously, yielding a stability score between 1 and 3 for 
each peptide. Peptides were categorized as CRL substrates if they exhibited >5-fold 
enrichment in either MLN4924-responsive population compared to the corresponding starting 
populations (Bin1 and Bin2) (Table S7). Substrates of KLHDC2, KLHDC3 or KLHDC10 
were identified by examining the sorted cells that contained stabilized GFP-peptide fusions 
following CRISPR-mediated ablation of each adaptors. Peptides were classified as substrates 
if, with both of the two independent sgRNAs, they exhibited >2.5-fold enrichment over the 
unsorted starting population, >3-fold enrichment over the control sorted populations (those 
transduced with either Cas9 alone or Cas9 plus the sgAAVS1 control guide), and were 
identified with at least 100 reads in the sorted sample (Table S8). The logoplots presented in 
Figure 4E were generated using Seq2Logo (Thomsen and Nielsen, 2012) from a custom 
position-specific scoring matrix. Amino acids were included on the plots if (1) >10% of the 
substrates (>9% for KLHDC10) contained the residue at that position, and (2) if the observed 
frequency of the amino acid was enriched >1.5-fold over the overall frequency across the 
whole G-end GPS-peptidome library. 
 
C-termini GPS-peptidome screen.  
Illumina reads were trimmed with Cutadapt and resulting 69 nt reads that perfectly mapped 
the reference sequence were enumerated using Bowtie 2. Following read count correction for 
sequencing depth, a PSI score was calculated for each peptide (yielding a score between 1 
and 4) and CRL substrates were identified based on a cut-off of a >5-fold enrichment in 
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either MLN4924-responsive population compared to the corresponding starting populations 
(Bin1 and Bin2) (Table S9). CRL substrates were further categorized as either CRL2 
substrates or CRL4A and/or CRL4B substrates based on their enrichment in the stabilized 
populations isolated by FACS following expression of dominant-negative Cullin constructs if 
the following criteria were all met: >2.5-fold enrichment over the unsorted starting 
population, >3-fold enrichment over the sorted population transduced with an empty 
expression vector, >10-fold enrichment over the other dominant-negative (DN) Cullin sorted 
population (ie. over both the DN Cul4A and DN Cul4B sorted populations for potential 
CRL2 substrates, and over the DN Cul2 sorted population for potential CRL4 substrates) and 
covered at a read depth of at least 1000 reads in the sorted sample (Table S12). For the 
scatterplot shown in Figure 5C, first the total number of acidic (D or E) or bulky aromatic (F, 
W or Y) residues in each peptide were counted, and then, for each value between 0 and 10, 
the mean PSI of all the peptides containing that number of acidic or aromatic residues was 
calculated. 
The stability data derived from the C-termini GPS-peptidome screen was used to predict 
potential destabilizing C-terminal degron motifs. We focused the search on the last six amino 
acids of each peptide. Varying two residues at a time, for all possible combinations of di-
peptide motifs (allowing gaps) we computed the mean PSI of all the peptides containing the 
motif at the extreme C-terminus. To focus the search on motifs that only act as degrons 
specifically when located at the end, as a reference we computed the mean PSI of all other 
peptides in the library that contained the motif at an internal position on the 23-mer peptides. 
To predict whether destabilizing C-terminal motifs were targeted by Cullin-family ligases, for 
each motif we computed the proportion of peptides ending with that motif identified as CRL 
substrates from the MLN4924-responsive populations and compared it to the proportion of 
peptides harboring that motif at an internal position on the peptides identified as CRL 
  
54 
substrates. The boxplots in Figures 5F and 7B display the distribution of PSI scores for all 
peptides in the C-termini GPS-peptidome library containing the indicated motif either at the 
extreme C-terminus of the peptide (colored boxes) or at an internal position in the peptide 
(gray boxes). For the data presented in Figure 7A, C-terminal motifs exhibiting <1.5-fold 
enrichment for CRL substrates were considered potential non-CRL substrates. The full data 
for each peptide is presented in Table S10. 
DATA AND SOFTWARE AVAILABILITY  
We are in the process of uploading the raw sequencing data to the SRA database. 
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KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Mouse anti-Vinculin Sigma-Aldrich  V9131 
Rat anti-HA-peroxidase Sigma-Aldrich  1201381900 
Mouse anti-p14ARF Cell Signaling Technology 2407 
Rabbit anti-MAGEA3 Abgent AP6165a 
Rabbit anti-PTOV1 Abcam ab81173 
Rabbit anti-TSPYL1 Abcam ab95943 
Rabbit anti-GFP Abcam ab290 
Rabbit anti-CCT5 Bethyl A303-480A 
Goat Anti-Rabbit IgG (H+L) HRP Jackson Immuno Research 111-035-003 
Goat Anti-Mouse IgG (H+L) HRP Jackson Immuno Research 115-035-003 
Chemicals, Peptides, and Recombinant Proteins 
MG132 R&D Systems 1748/5 
Bafilomycin A1 Enzo Life Science BML-CM110-0100 
MLN4924 Active Biochem A-1139 
Polybrene Santa Cruz sc-134220 
HA peptide Sigma-Aldrich  I2149 
Critical Commercial Assays  
NEBNext DNA Library Prep kit New England Biolabs E7370S 
PURExpress In Vitro Protein Synthesis Kit New England Biolabs E6800S 
QIAEX II Gel Extraction Kit Qiagen 20051 
PCR purification kit Qiagen 28106 
Gentra Puregene Cell Kit Qiagen 158767 
Deposited Data 
Awaiting accession number from SRA   
   
   
   
   
Experimental Models: Cell Lines 
HEK-293T ATCC ATCC® CRL-3216™ 
A375 Carl Novina lab  
   
   
   
Experimental Models: Organisms/Strains 
   
   
   
   
   
   
Oligonucleotides 
sg1-APPBP2: GATGTAGTTGTCCACGACAG This paper NA 
sg2-APPBP2: GGATGTTCTCGGGCAAGGAG This paper NA 
sg1-KLHDC2: GGCCACATGTTCGTCTGGGG  This paper NA 
sg2-KLHDC2: GAGCTTCCTGACATAGAAGG  This paper NA 
sg1-KLHDC3: GCGGTGGACAGTGCACCTGG  This paper NA 
sg2-KLHDC3: GGGGCAGCCCTGCACGCTGG  This paper NA 
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sg1-KLHDC10: GCCTCCGCCACCAGCGCCGG This paper NA 
sg2-KLHDC10: GGGCGCCTCCTCCCCTCCGG This paper NA 
sgFEM1A: GGCGCGAGCGTGGAGGCCGG  This paper NA 
sgFEM1C: GTCAAGGTGCCCATACCTGG This paper NA 
sgCUL2: GTTGACGACAATAAAAGCCG This paper NA 
sgDACF12: GCAACTTCCCAGTCTCCTGA This paper NA 
sg1-TRPC4AP: GATAGCCTCCATGGAGAGAAG This paper NA 
sg2-TRPC4AP: GAGGCCTACGATCTCTATCCG This paper NA 
sgAAVS1: GGGGCCACTAGGGACAGGAT This paper NA 
Recombinant DNA 
pHAGE-GPS3.0-DEST This paper NA 
pHAGE-CMV-DEST-PGKpuro 3’BC This paper NA 
barcoded GPS-ORFeome expression library This paper NA 
pHAGE-GPS3.0-peptide libraries This paper NA 
pHAGE-Flag-HA-DEST This paper NA 
lentiCRISPR v2 Addgene 52961 
Software and Algorithms 
Bowtie 2 Langmead and Salzberg, 
2012; Langmead et al., 2009 
 
Cutadapt Martin, 2011  
MAGeCK Li et al., 2014  
BLAT Kent, 2002  
Seq2Logo Thomsen and Nielsen, 2012  
Seaborn visualization library for Python https://seaborn.pydata.org/  
Other 
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 SUPPLEMENTAL TABLE LEGENDS 
Table S1. Results from the CRISPR screens on the GPS-peptidome CRL2 clones as 
analyzed by MAGeCK, Related to Figure 1. 
Table S1A contains the results for Clone 1. 
Table S1B contains the results for Clone 2. 
Table S1C contains the results for Clone 3. 
Table S1D contains the results for Clone 4. 
Table S1E contains the results for Clone 5. 
Table S1F contains the results for Clone 6. 
Table S1G contains the results for Clone 7. 
Table S1H contains the results for Clone 8. 
Table S1I contains the results for Clone 9. 
Table S1J contains the results for Clone 10. 
Table S1K contains the results for Clone 11. 
Table S1L contains the results for Clone 12. 
Table S1M contains the results for Clone 13. 
Table S1N contains the results for Clone 14. 
Table S1O contains the results for Clone 15. 
Table S1P contains the results for Clone 16. 
Table S1Q contains the results for Clone 17. 
 
Table S2. Amino acid sequences of the GFP-peptide fusions in the 17 clones, Related to 
Figure 1. 
 
 
Table S3. GPS-ORFeome screen data, Related to Figure 2. 
Table S3A contains raw GPS data for each barcoded ORF across the five bins and in the 
three MLN4924-responsive populations. 
Table S3B contains collapsed GPS data for each ORF. 
 
Table S4. Alanine scanning mutagenesis experiments for five KLHDC3 substrates 
clones, Related to Figure 4. 
Table S4A contains the results for Clone 3.  
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Table S4B contains the results for Clone 5.  
Table S4C contains the results for Clone 6. 
Table S4D contains the results for Clone 7.  
Table S4E contains the results for Clone 8. 
 
Table S5. Saturation mutagenesis experiments of peptides bearing C-end degron, 
Related to Figure 4, 5 and 6. 
Table S5A contains saturation mutagenesis of KLHDC3 substrate Clone 8. 
Table S5B contains saturation mutagenesis of KLHDC2 substrate EPHB2. 
Table S5C contains saturation mutagenesis of KLHDC2 substrate PDGFC. 
Table S5D contains saturation mutagenesis of KLHDC3 substrate EMID1. 
Table S5E contains saturation mutagenesis of KLHDC3 substrate CHGA. 
Table S5F contains saturation mutagenesis of APPBP2 substrate XP_211896. 
Table S5G contains saturation mutagenesis of APPBP2 substrate peptide #35 (Table S11). 
Table S5H contains saturation mutagenesis of DCAF12 substrate MAGEA3. 
Table S5I contains saturation mutagenesis of TRPC4AP substrate MSRB2. 
Table S6. Amino acid sequences of KLHDC3 peptide substrates identified from the 
original GPS-peptidome screen, Related to Figure 4. 
 
Table S7. G-end GPS-peptidome library screen data, Related to Figure 4. 
 
Table S8. Amino acid sequences of the peptide substrates of KLHDC2, KLHDC3 and 
KLHDC10 identified from the G-end GPS library, Related to Figure 4.  
Table S8A contains KLHDC2 substrates. 
Table S8B contains KLHDC3 substrates. 
Table S8C contains KLHDC10 substrates. 
 
Table S9. C-terminal 23-mer GPS-peptidome library screen data, Related to Figure 5. 
 
Table S10. Computational prediction of C-terminal degrons, Related to Figures 5, 6 and 
7. 
 
Table S11. Amino acid sequences of APPBP2 peptide substrates identified from original 
GPS-peptidome screen, Related to Figure 5. 
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Table S12. Amino acid sequences of CRL2 and CRL4A/B substrates from the C-
terminal 23-mer GPS-peptidome library, Related to Figure 6. 
Table S12A contains CRL2 substrates. 
Table S12B contains CRL4A substrates. 
Table S12C contains CRL4B substrates. 
Table S12D contains shared CRL4A and CRL4B substrates. 
 
Table S13. Results from the CRISPR screens of the CRL2 and CRL4 substrate C-
terminal 23-mer peptides as analyzed by MAGeCK, Related to Figure 6. 
Table S13A contains the results for the CDK5R1 construct (R-end). 
Table S13B contains the results for the SIL1 construct (R-end). 
Table S13C contains the results for the MAGEA3 construct (EE-end). 
Table S13D contains the results for the SAT1 construct (EE-end). 
Table S13E contains the results for the MGAT2 construct (R-3 motif). 
Table S13F contains the results for the NPPB construct (R-3 motif). 
Table S13G contains the results for the MSRB2 construct (R-3 motif).  
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